Nonglycosylated erythropoietin bearing acetamidomethyl protecting groups at the cysteine residues has been synthesized via chemical methods. Alanine ligation was used to assemble four peptide fragments, themselves prepared by solid phase peptide synthesis. This work outlines a route for the synthesis of homogeneous glycosylated erythropoietin.
ligation between a C-terminal thioester (2) and an N-terminal amino acid surrogate containing a temporary thiol functionality (3); followed by (ii) removal of the thiol group of the resultant peptide via metal-based or metal-free desulfurization (MFD) (13) , to yield the native peptide sequence (see 4 → 5, Scheme 1). These noncysteine NCL-inspired ligations, many of which were developed in our laboratory, would seem to be of great value in the chemical synthesis of proteins. EPO protein is a particularly challenging case, in that the four native cysteine residues are positioned near the termini, thus rendering them less attractive as ligation sites.
In the research described below, the total synthesis of nonglycosylated EPO was identified as our goal. Since the glycans play a significant role in the stability and solubility of EPO, it would be of great interest to learn about the behavior of the nonglycosylated EPO protein as a baseline in documenting the effects of glycosylation on EPO's chemical viability and biological performance. In essence, we sought to determine the chemical stability and overall manageability of nonglycosylated EPO protein. We hoped to gain access to the intended substrates via a concise chemical synthesis. Earlier routes to nonglycosylated EPO involved eukaryotic recombinant gene expression followed by enzymatic degradation of the oligosaccharides (6) , and recombinant gene expression in Escherichia coli (19) . It should also be noted that the chemical synthesis of several EPO inspired constructs have been reported (20, 21) .
At the same time, we aimed to evaluate the scope and limitations of new methodologies we introduced in simpler systems, which in our judgment serve to enhance the power of Kent's NCL discovery. In particular, we hoped to exploit the power of relatively stable ortho-thiopenolic esters (22) as surrogates for reactive arylthioesters. Unveiling of the latent thioester commences with reduction of the disulfide bond of 6 to form aryl thiol 7, which isomerizes to thioester 2 by O → S acyl transfer (Scheme 2). The now thio-activated C terminus participates in an NCL reaction with a second peptide (3), bearing an N-terminal thiol functionality, to afford peptide 4.
Results and Discussion
Building upon the strategy employed in the syntheses of our previously published glycosylated EPO fragments (23) (24) (25) , EPO protein was envisioned, at the level of retrosynthesis, to arise from four fragments of roughly comparable size (Scheme 3, see peptides 8-11). We anticipated accomplishing iterative mergers of these peptide segments through de facto alanine ligation. Upon formation of peptide 12 through sequential ligation of peptide segments 8-11, MFD of the nonnative cysteine residues would complete the synthesis of acetamidomethyl (Acm)-protected nonglycosylated EPO (13) . Removal of the Acm protecting groups was anticipated by analogy to other ongoing work in our laboratory in glycoprotein synthesis.
The C-terminal ortho-arylthioester peptide segments (8-10) were prepared by single amino acid attachments to protected peptide fragments (Scheme 4). As a representative example, the synthesis of Ala 1 -Cys 29 (8) is detailed in Scheme 4A. Thus, resinbound peptide 14 was prepared by Fmoc-based solid phase peptide synthesis using NovaSyn TGT resin and single amino acids (with the exception of the Asp-Ser pseudoproline dipeptide residue shown in Scheme 4B). Following completion of the synthesis, the crude protected peptide 15 was cleaved from the resin by treatment with acetic acid solution. The final amino acid, Acm-protected cysteine 16, bearing the ortho-thiophenolic ester, was incorporated by single amino acid attachment under Sakakibara conditions (26) . The acid-labile protecting groups were removed by treatment of the reaction mixture with Cocktail B (88% TFA, 5% H 2 O, 5% phenol, 2% TIPSH). After purification by high-performance liquid chromatography (HPLC), peptide 8 was isolated in 38% yield from crude peptide 15. Peptides Thz 30 -Gln 78 (9) and Thz 79 -Arg 166 (10) (Scheme 4C) were prepared through analogous procedures, involving single amino acid attachment to the protected peptide under epimerization-free Sakakibara conditions (26) followed by removal of the acid-labile protecting groups with Cocktail B. The fourth fragment, peptide 11 (shown in Scheme 5), was prepared by treatment of the resinbound protected peptide with Cocktail B. The four fragments (8) (9) (10) (11) were sequentially merged through a series of iterative NCL/thiazolidine removal sequences (Scheme 5). Thus, peptide 11, possessing an N-terminal cysteine residue, and peptide 10, bearing a latent C-terminal thioester, were combined in phosphate buffer solution containing guanidine•HCl, TCEP•HCl, and MPAA at pH 7.2-7.4. Following completion of the ligation, the thiazolidine (27, 28) was unmasked through addition of MeONH 2 •HCl (pH 4.0) to reveal an N-terminal cysteine. The crude reaction mixture was purified by HPLC to yield Cys 79 -Arg 166 (17) in 34% yield (2 steps). Next, Cys 30 -Arg 166 (18) was prepared in 42% yield through ligation of peptide 17 with peptide 9, followed by thiazolidine removal. To complete the assembly of the amino acid sequence, the N-terminal peptide 8 was subjected to NCL reaction conditions with Cys 30 -Arg 166 (18) . The product of this reaction, peptide 12, exhibited poor solubility properties in mixtures of acetonitrile and water and thus could not be purified by HPLC. However, excess peptide 8, and components of the buffer solution, including small organics and salts, could be removed by size exclusion centrifugal filtration. Fortunately, peptide 12 could be characterized by liquid chromatography-mass spectrometry (LC-MS), despite its poor solubility properties. The unprotected, nonnative cysteines at positions 30, 79, and 125 of peptide 12 were converted to the native alanine residues through MFD (13) with water-soluble radical initiator VA-044 to generate Acmprotected nonglycosylated EPO (13) (67% yield). The product was purified by centrifugal filtration and characterized by LC-MS. The logic of the synthetic plan inherent in the proposed transformation of 12 → 13 had been vindicated.
Interestingly, Ala 1 -Arg 166 (12) and Cys 30 -Arg 166 (18) exhibited notably different stability characteristics. Peptide 18 could be purified by reverse-phase HPLC in water/acetonitrile solutions and seemed to display quite manageable solubility characteristics. However, peptide 12, while clearly present, could not be properly purified by HPLC, most likely due to problems arising from poor solubility and aggregation. Thus ligation of the 29-amino acid segment encompassed in peptide 8 with peptide 18 had resulted in a protein with significantly decreased viability. This finding is an important benchmark for evaluating the effects of glycosylation on protein viability.
The Acm groups of peptide 18 were removed to yield the fully deprotected Cys 30 -Arg 166 segment (19) . Although this reaction highlights the ability to remove the Acm groups, synthesis of EPO protein by alanine ligation of peptide 19 with a fully deprotected Ala 1 -Cys 29 domain is complicated by the presence of both unprotected native and nonnative cysteine residues. This scenario would present the challenging task of performing the selective desulfurization of nonnative cysteine residues in the presence of unprotected native cysteine residues. However, EPO protein could be assembled from completely unprotected fragments by shifting the final ligation by one amino acid to Gly 28 and Cys 29 . This alternative strategy would not require a subsequent global desulfurization since the final step would be a standard NCL reaction.
Conclusion
In summary, we have synthesized nonglycosylated EPO (13), containing four Acm-protected cysteine residues, through the convergent merger of four peptide fragments. Formal alanine ligation via the sequence of NCL-initiated by an o-mercaptoaryl ester rearrangement (OMER) driven thioester formation-and MFD has been shown to be an effective means for constructing the full EPO peptide. Remarkably, concurrent threefold MFD has been demonstrated on a 166-amino acid peptide, and its compatibility with Acm protecting groups has been established. These findings, rather interesting in their own right, have significant implications for the chemical synthesis of homogeneous EPO itself. This matter is being pursued using the logic described above, albeit with discrete, relevant glycans in their proper places.
Materials and Methods
Commercial reagents were used without further purification. Automated peptide synthesis was performed on an Applied Biosystems Pioneer S3 continuous flow peptide synthesizer. Peptides were synthesized under standard automated Fmoc protocols. NMR spectra ( 1 H and 13 C) were recorded on a Bruker Advance DRX-600 MHz spectrometer. Low-resolution mass spectral analyses were performed with a JOEL JMS-DX-303-HF mass spectrometer or Waters Micromass ZQ mass spectrometer. High-resolution mass spectral analyses were performed by MSKCC core facility staff. The deblock solution was a mixture of 96∶2∶2 of DMF/piperidine/DBU. Upon completion of automated synthesis on a 0.05-0.2 mmol scale, the peptide resin was washed into a peptide synthesis vessel with MeOH. After drying, the resin was subjected to a cleavage cocktail of acetic acid/trifluoroethanol/methylene chloride (1∶1∶3, 3 × 2-6 mL) for 45 min. The resulting cleavage solutions were combined and concentrated. The oily residue was suspended in acetonitrile/water (1∶1, 0.05% trifluoroacetic acid) and then lyophilized.
Analytical LC-MS was performed using a Waters 2695 Separations Module and a Waters 2996 Photodiode Array Detector equipped with a Varian Microsorb C18 column (150 × 2 mm) or a Waters X-Bridge C8 column (150 × 2.1 mm) or a Varian Microsorb C8 column (150 × 2 mm) at a flow rate of 0.2 mL∕ min. Preparative HPLC was performed using a Rainin HPXL solvent delivery system equipped with a Rainin UV-1 detector using either a Varian Microsorb 100-5 C18 column (250 × 21.4 mm) or a Waters X-Bridge C8 column (150 × 19 mm) at a flow rate of 16 mL/min. The mobile phase was comprised of a linear gradient of 0.05% TFA (v∕v) in water (solvent A) and 0.04% TFA (v∕v) in acetonitrile (solvent B).
Centrifugal filtrations were performed using an Eppendorf 5804 R Centrifuge and Millipore Amicon Ultra-4 Centrifugal Filters (10 kD cut-off). Buffer solutions were diluted with acetonitrile/water (1∶4, 0.05% trifluoroacetic acid) to 4 mL total volume in a Millipore centrifugal filter tube. The tube was centrifuged at 4,000 rpm until residual volume was 0.25-0.5 mL. The residual volume was diluted to 4 mL, and the process was repeated four times. The residual solution was diluted with acetonitrile/water (1∶1, 0.05% trifluoroacetic acid) and the solution was lyophilized.
Native chemical ligation buffer was prepared by dissolving guanidine•HCl (1.146 g, 6M) in water. The solution was diluted to 2 mL, then Na 2 HPO 4 (56 mg, 0.2M) was added to the solution, followed by TCEP•HCl (10.8 mg, 0.02M). The pH of the solution was adjusted to 7.2-7.4 by the addition of NaOH solution (5M). The solution was sonicated and sparged with Ar for 15 min. 4-Mercaptophenylacetic acid (67 mg, 0.2M) was added, and the pH of the solution was adjusted to 7.2-7.4 by the addition of NaOH solution (5M). The solution was sonicated and sparged with Ar for 15 min.
The acid-labile side chain protecting groups were cleaved by treatment with Cocktail B consisting of trifluoroacetic acid (88% by volume), water (5% by volume), phenol (5% by weight), and i Pr 3 SiH (2% by volume). The solution was triturated with ice-cold diethyl ether (3 × 35 mL) to give a white precipitate. The suspension was centrifuged and the supernant was decanted. The precipitate was solubilized in water/acetonitrile (1∶1, 0.05% trifluoroacetic acid), then lyophilized.
A detailed description of materials and methods is given in SI Appendix.
